Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
fatty liver disease
Biotech
Ionis raises hand in MASH race, shows liver gains in ph. 2 test
With the FDA due to approve Madrigal's MASH drug, Ionis is raising its hand to showcase a phase 2 asset that has improved symptoms of the disease.
Annalee Armstrong
Mar 13, 2024 9:54am
Boehringer links GLP-1 agonist to scarring improvements in MASH
Feb 26, 2024 6:17am
Inventiva pauses MASH study over patient's raised liver enzymes
Feb 16, 2024 8:15am
Hepatitis B drug developers chart slow progress, just like hep C
Nov 14, 2023 9:05am
Inventiva stock climbs on delayed data from liver disease trial
Jun 14, 2023 6:00am
Organoids offer NAFLD insights and potential drug target
Feb 28, 2023 12:27pm